Levensten
Law Firm Making AndroGelTM FDA Freedom of Information Act Documents
Available to Public on Its Websites for Free
PHILADELPHIA, PA – February 18, 2014 - The Levensten Law
Firm, P.C. of Philadelphia, PA announces that pursuant to a Freedom of
Information Act request (FOIA), the Food and Drug Administration (FDA) produced
thousands of documents to the firm regarding potential health risks associated
with AndroGelTM, a prescription testosterone supplement marketed by AbbVie.
The FDA Adverse Event
Reports contained in the production show that between the years of 2002-2013,
there were approximately 44 pulmonary embolisms, 42 heart attacks, 18 cerebral
vascular accidents, and 12 deaths, among other injuries, reported for patients
taking AndroGel during that time period.
“We believe these
reports are the tip of the iceberg,” said Scott Levensten, Esq., Principal,
Levensten Law Firm. “It’s important that this information gets out to the
public as quickly as possible, not only for the people who are currently on the
medication, but for those who are considering it.”
On January 31,
2014, the FDA issued a Safety Alert that it’s reassessing the safety of
AndroGelTM and other prescription testosterone products
after two separate studies showed that these products may increase the
cardiovascular risks in some men. Several additional studies are ongoing. The
AndroGelTM label and medication guide do not currently
warn of the risk of heart attack, stroke and death potentially associated with
the medication. Five AndroGelTM lawsuits were recently filed in federal court
in the state of Illinois by patients who allege that they suffered
cardiovascular injuries.
“Our firm anticipates
that the absence of any warning, coupled with documents produced by the FDA and
AbbVie, in the backdrop of the massive low testosterone marketing campaigns
that are ongoing, will set the stage for a large mass tort AndroGelTM federal Multidistrict Litigation and consolidated
state court litigation” continued Scott Levensten Esq.
The Levensten Law Firm
is making the FDA FOIA documents, along with the AndroGelTM label, medication guide, and recent studies,
available to the public at no charge
on its websites www.levenstenlawfirm.com and www.Androgellawyers.com.
For more information
concerning the risks of prescription Testosterone products, please contact
Scott Levensten, Esq. at the Levensten Law Firm, by phone at 215-545-5600 or by
email sdl@levenstenlawfirm.com.
About The Levensten Law Firm
The Levensten Law Firm, P.C., is among this
Country's leading plaintiffs' mass tort litigation firms. Mr. Levensten has
been committed to representing victims of defective drugs and medical devices
in federal and state courts nationwide for nearly two decades. Mr. Levensten
was named a Pennsylvania SuperLawyer for the past 10 years in a row for his
achievements in the area of mass torts. Additional information is
available at http://www.levenstenlawfirm.com and http://www.androgellawyers.com, as well as on Twitter at http://www.twitter.com/pharmainjurylaw and on Google+ at http://www.google.com/+ScottLevensten.